Mogrify keeps long-term IPO options open
Transformational biopharma company Mogrify in Cambridge has made another significant senior hire by persuading former Johnson & Johnson executive Tom Graney to become a non-executive director, audit chair and capital markets adviser.
He joins senior biopharma industry executives Dr Jane Osbourn (Chair) and Dr Lorenz Mayr as an independent member of the board.
The appointment is being seen in the life science industry as a logical step towards an IPO with the US first choice but Asia and London also options –although a float is unlikely until around the end of 2024 judging by the current growth trajectory.
Still the rising potency and experience of the board indicates that Mogrify is on course for greatness via development of a new class of in vivo reprogramming therapies and by transforming the development of ex vivo cell therapies; its exciting technology is tempting serious talent to climb on board.
Graney is a seasoned financial executive with more than 25 years’ global experience spanning corporate development, commercial strategy, portfolio management and value creation for both public and private biopharma companies.
He was CFO at Vertex Pharmaceuticals, Ironwood Pharmaceuticals and Generation Bio after a long career at Johnson & Johnson, which included four years as worldwide VP of Finance and CFO of Ethicon.
Most recently he has been appointed CEO-CFO of Oxurion, a clinical-stage biopharmaceutical company developing next-generation ophthalmic therapies.
He has already helped raise more than $500 million on both private and public capital markets.
Mogrify CEO Dr Darrin Disley, said: “We are honoured to welcome Tom to the board following the recent appointment of Dr Louise Modis as CSO.
“His appointment further strengthens our leadership team, which includes industry influencers in platform technologies, drug development and biopharma company building.
“Tom joins us after many months of ongoing support which is a testament to his dedication to nurturing innovation towards impactful medicines for patients.
“Tom’s considerable experience in both public and private settings, expertise in financial planning and structuring and knowledge of US capital markets will allow Mogrify to strengthen its position in the lead up to cross-over funding rounds and ultimately an IPO.”
Graney said: “Mogrify has shown enormous progress over the past 12 months. The company’s innovative suite of cellular reprogramming and delivery technologies hold unique and scalable potential to underpin the development of novel in vivo and ex vivo treatments for patients with few alternatives.
“I am looking forward to working with the world-class team as they translate this deep expertise in cellular reprogramming into the advancement of internal programs in ophthalmology, immuno-oncology and other disease areas through to first-in-human studies.”